Kornimate/medical-research-clean huggingface dataset:
effect of a family empowerment program on coping, problem solving in parents, and quality of life in children with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: parents of children with cystic fibrosis (cf) experience high levels of stress and problems. family empowerment interventions provide important support for many patients with cf and their families. however,there is a lack of research exploring the effects of such empowerment programs on coping, and problem solving among parents, and quality of life in children with cf. the present study aimed to assess the effect of a family empowerment program-based nursing intervention on parents coping with stress and problem solving, and quality of life children with cf.

parents of children with cystic fibrosis (cf) experience high levels of stress and problems. family empowerment interventions provide important support for many patients with cf and their families. however,there is a lack of research exploring the effects of such empowerment programs on coping, and problem solving among parents, and quality of life in children with cf. the present study aimed to assess the effect of a family empowerment program-based nursing intervention on parents coping with stress and problem solving, and quality of life children with cf. a single-blinded, parallel group pretest and posttest design randomized controlled trial was used. data were collected over 5 months (january 2017-may 2017) from 48 participants in a medical faculty hospital. they were randomly assigned to the experimental (n = 24) and control (n = 24) groups. nursing interventions applied to the experimental group for ten weeks with the intent of strengthening families consist of; providing individualized training and booklet concerning disease management and providing phone calls and consultancy services for the purpose of reinforcing the training and increasing the motivation. a routine polyclinic follow-up was applied to the control group. problem solving inventory (psi), scale of ways of coping with stress (swcs), and the cystic fibrosis questionnaire-revised scale (cfq-r) were used reliable and valid instruments. the data were evaluated using the wilcoxon signed ranks test in evaluating dependent groups and the mann-whitney u test in independent groups.

Eligibility criteria:
inclusion criteria: * children aged 6-18 years old; * pulmonary functions forced expiratory volume (fev 1) over 40% * being able to communicate in turkish, * voluntary parents in the study. exclusion criteria: * had mental disorders; * receiving mechanical ventilation; * being in the process of lung transplantation; * having a sister/brother who died due to cf * being in enteral or parenteral feeding; * having a chronic disease other than cf.

Keywords: children with cystic fibrosis parents quality of life coping with stress problem solving family empowerment program nursing
clinical performance and safety investigation of endometrial washing medical device forielle

Conditions: Infertility

Summary: this is a multicenter, prospective randomized controlled, interventional investigation to assess the safety and clinical performance of forielle, a medical device for endometrial washing, in restoring favorable endometrial condition to implantation after controlled ovarian stimulation (cos) during assisted reproductive technique (art).


Eligibility criteria:
inclusion criteria: * all infertile women treated with intracytoplasmic sperm injection (icsi)/fertilization in vitro and embryo transfer (fivet) * less than or equal to (\<=) 1 previous failed embryo transfer * eumenorrheic normo-gonadotropic women * basal follicle-stimulating hormone (fsh) \<=12 international unit per liter (iu/l) * anti-mullerian hormone (amh) greater than (\>) 1.1 nanogram per milliliter (ng/ml) * ovarian reserve: number of antral follicles 2 millimeter (mm) between 6 \<= antral follicle count (afc) \<= 16 * follicles \> 16 mm at the triggering day between 5-14 * body mass index (bmi) between 18 \<= bmi \<= 27 kilogram per meter square (kg/m\^2) * indication for fresh embryo transfer * normal uterine cavity on ultrasound exam (e.g., no presence of hydrosalpinx) * undergoing assisted reproductive technique (art) and oocyte maturation by human chorionic gonadotropin (hcg) triggering * progesterone (p4) serum level at the hcg triggering day \<= 1.5 ng/ml (day o/randomization) * estradiol (e2) \<= 3000 picogram/milliliter (pg/ml) at the human chorionic gonadotropin (hcg) triggering day (day 0/randomization) * subjects must have read and signed the informed consent form prior to study-specific-procedures not part of standard of care * other protocol defined inclusion criteria could apply exclusion criteria: * clinically significant systemic disease (such as diabetes, metabolic syndrome, immunological diseases, diagnosed thrombophilia, porphyria, or any other medical condition requiring the use of low-molecular weight heparin therapy) * polycystic ovary syndrome (pcos) according to rotterdam consensus criteria (european society of human reproduction and embryology \[eshre\]/american society for reproductive medicine \[asrm\], 2003) * poor ovarian response (por) according to the european society of human reproduction and embryology (eshre) criteria * rif (repeated implantation failure), defined as greater than or equals to (\>=) 2 previous failed embryo transfers * endometriosis iii-iv stage or adenomyosis * clinically significant findings on exam or ultrasound, such as salpingitis, hydrosalpynx or evidence of ovarian cysts * known hypersensitivity to any of the components of the solution * known hypersensitivity to vaginal progesterone or its excipients * other protocol defined exclusion criteria could apply

Keywords: infertility forielle assisted reproductive technique (art) controlled ovarian stimulation (cos)
text messaging and atopic dermatitis

Conditions: Atopic Dermatitis

Summary: atopic dermatitis is a common problem faced by patients of all ages and backgrounds. treatment regimens and specific therapies may be time consuming and multiple studies have documented a parallel decrease in compliance as time after an office visit increases. the adolescent population is an extremely challenging sub-group of patients in terms of complying with a treatment regimen. not only are they striving for independence and thus lacking supervision of a regimen by a parent, but their complex thinking skills are immature, leading to forgetful behavior. by introducing a reminder system for these vulnerable patients that is easily incorporated into their daily lives, the investigators propose that patients will have better compliance at applying their medication and thus improving their atopic dermatitis. text-messaging via cell phones has become very popular among teenagers and adults and provides a non-obtrusive method of sending a treatment reminder.

we propose to conduct a randomized, controlled 6-week trial to evaluate the impact of a text message-based reminder program on adherence to health maintenance behaviors among adolescents diagnosed with atopic dermatitis. after obtaining informed consent, subjects will be randomized into either an intervention or control group. subjects in the intervention group will receive a daily text message with a tailored message regarding atopic dermatitis, while control group subjects will receive a weekly text message with information on local weather, sport or news without any reference to atopic dermatitis. of note, the decision to send a weekly text message to the control group reflects the expectation that a message will be sent, although the frequency and content of the message will not be revealed.

Eligibility criteria:
inclusion criteria: * age 10-17 inclusive * capable of giving informed consent/assent. of note, all subjects will sign an assent form and parents will sign a parent consent form. * diagnosed with atopic dermatitis by a physician (self report) * iga score fo 2 or greater * currently using at least one prescribed topical therapy for atopic dermatitis * have a mobile phone capable of receiving text messages * able to retrieve text messages from mobile phone * able to adhere to study visit schedule and other protocol requirements. exclusion criteria: * younger than 10 years of age or 18 years and older at the time of enrollment * no diagnosis of atopic dermatitis by a physician * iga score of 0 or 1 * currently on no prescribed topical treatment for atopic dermatitis * uv therapy or climatotherapy is a part of treatment for atopic dermatitis * does not have a mobile phone capable of receiving text messages * unable to retrieve text message * non-english speaking individuals (text messages are in english)

Keywords: adherence text message reminder adolescents
colorectal cancer screening for cancer survivors

Conditions: Colorectal Cancer

Summary: the risk of colorectal cancer (crc) is significant among cancer survivors treated with abdominal radiation therapy (rt). further, crc is once of the few cancers for which there is effective screening. although some expert groups recommend early crc screening for patients with prior abdominal rt, the effectiveness of early screening is unknown. it is also unknown if radiation-induced crc passes through a "pre-clinical" phase in which precancerous polyps are detectable and treatable prior to becoming invasive cancers. this study will evaluate whether screening will detect pre-invasive colorectal polyps among survivors treated with rt.

cancer survivors meeting the cog criteria for crc screening will undergo colonoscopy and removal of colorectal polyps. documentation of polyp number, location and pathologic characteristics will be made. clinical data information will also be collected at the time of patient enrollment.

Eligibility criteria:
inclusion criteria: 1. asymptomatic survivors treated with ≥ 25gy to the abdomen, pelvis or spine, or ≥ 12gy total body radiation therapy, or ≥ 12gy whole abdominal rt. 2. patients who have passed ≥10 years following rt 3. patients whose current age is 35-49. exclusion criteria: 1. patients with signs/symptoms suggestive of crc or other high-risk features such as: * persistent constipation for \>2 weeks in the last month * one or more unexplained episodes of red blood in the stool in the last month * one or more unexplained episodes of black stool in the last month * unexplained pelvic pain in the last month 2. patients with a history of crohn's disease or ulcerative colitis 3. patients already taking part in a colorectal screening program defined as any colorectal screening (colonoscopy, sigmoidoscopy, fecal occult blood test) within last 5 years. 4. patients with self-reported history of colorectal polyps.

Keywords: colorectal cancer screening cancer survivor radiation therapy
efficacy and tolerability of mk0533 in patients with type 2 diabetes (0533-005)

Conditions: Diabetes Mellitus Type 2

Summary: a study to evaluate the effectiveness and tolerability of mk0533 and pioglitazone in patients with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18 to 70 years with type 2 diabetes who have not been able to adequately control their blood glucose levels * note: only patients who have not been taking any antihyperglycemic medicine for 3 months will be screened exclusion criteria: * patients taking any medicines that affect body fluid level such as a diuretic or water pill * patients taking niacin or other certain medications * patients with any of the following conditions: liver or kidney disease, poorly controlled high blood pressure, heart disease or certain blood disorders * patients with abnormal laboratory results from a blood test that will be given before each patient starts the study
intravenous hydromorphone for the treatment of acute pain

Conditions: Acute Chest Pain

Summary: to observe the efficacy and safety of hydromorphone in the treatment of acute chest pain, and to explore the potential advantages of hydromorphone for analgesia in patients with acute chest pain, so as to provide more theoretical basis for individualized analgesia and rapid recovery in patients with acute chest pain.


Eligibility criteria:
inclusion criteria: 1. age 18-64 years old; 2. gender is not limited; 3. patients with acute chest pain, with the time from pain onset to visit the doctor ≤ 24 days; 4. severe pain that requires the use of opioids to control as determined by emergency physicians; 5. obtain informed consent from the patient or family members. exclusion criteria: 1. known allergy to hydromorphone or morphine; 2. systolic blood pressure \<100 mmhg, oxygen saturation \<95%, pulse less than 60 beats/min; 3. use of acetaminophen or nonsteroidal anti-inflammatory drugs in the past 8 hours; 4. chronic pain, defined as pain lasting for more than 12 weeks; 5. delirium, alcohol withdrawal symptoms or other drug intoxication; 6. pregnant or lactating women; 7. patients with mental or neurological diseases, cognitive and consciousness disorders and inability to express correctly; 8. participating in any other research at the same time; 9. factors that increase the risk of participating in the study (life-threatening chest pain patients who require rapid diagnosis or treatment intervention, such as resuscitation status, excluding chest pain caused by myocardial infarction), who are judged by the researchers to be unsuitable for inclusion in the study.
gene therapy for chronic granulomatous disease

Conditions: Granulomatous Disease, Chronic

Summary: the aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous cd34+ cells of the peripheral blood of chemotherapy conditioned (busulphan)patients with chronic granulomatous disease (cgd). also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented.


Eligibility criteria:
inclusion criteria: * x-linked chronic granulomatous disease * history of life-threatening severe infections * no hla-matched related or non-related donor * therapy resistent life threatening infections/organ dysfunction * no other treatment options e.g. bmt exclusion criteria: * \< 18 years of age * hiv infection * life expectancy \> 2 years * infections treatable by conventional therapy (antibiotics, allogeneic granulocytes)

Keywords: cgd
the role of cox-2 inhibition in salt sensitivity of blood pressure

Conditions: Hypertension

Summary: the purpose of this study is to determine if the drug celebrex changes the way the kidney gets rid of salt and maintains blood pressure.

there have been many studies done with analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs; however it is not understood how blood pressure changes while using celebrex. the study hypothesis is that celebrex will increase salt sensitivity of blood pressure.

Eligibility criteria:
inclusion criteria: * healthy men and women exclusion criteria: * history of heart disease * have had heart surgery * high blood pressure * diabetes * cancer * any other disease such as kidney or neurological diseases * taking medications such as aspirin or medicines for your heart or blood pressure * have asthma or are allergic to sulfa drugs * body mass index greater than 30 * use tobacco * pregnant * women using oral contraceptives or hormone replacement therapy

Keywords: salt sensitivity of blood pressure
totem: trial of tap block effective medications

Conditions: Pain, Postoperative

Summary: our goal is to determine if liposomal bupivacaine compared to standard bupivacaine results in increased pain control and decreased narcotic pain medication use when used in tap blocks prior to laparoscopic hysterectomies for benign indications.


Eligibility criteria:
inclusion criteria: * women undergoing non robotic assisted laparoscopic surgery for benign gynecologic conditions * english speaking exclusion criteria: * known current malignancy * contraindication to medications
streptoccus pseudopneumoniae atassiut universityhospitals

Conditions: Pneumonia; Streptococcus Infection

Summary: streptococcus pseudopneumoniae as suggested by dna-dna homology studies is recorded as a species of the streptococcus mitis/oralis members of viridans group streptococci; they have some similar features to the streptococcus mitis/oralis members of viridans streptococcus pneumoniae

principle characteristics of streptococcus. pseudopneumoniae are the lacking of pneumococcal capsule, bile insolubility, the indeterminate sensitivity or resistance to optochin after incubation in carbon dioxide (5%), while sensitivity to it after incubation in ambient air streptococcus . pseudopneumoniae was firstly described in sputum samples of patients with lower respiratory tract infection, particularly those with chronic obstructive pulmonarydiseases pseudopneumoniae is usually misidentified in our laboratories as we usually rely on optochin sensitivity testing with 5% carbon dioxide detection of streptococcus. pneumoniae and miss the incubation in ambient air which is the key point for identification of streptococcus. pseudopneumoniae. biochemical reactions are usually used to differentiate typical pneumoniae from streptococc streptococcus . pseudopneumoniae and other related streptococci; several molecular techniques have also been used there are several polymerase chain reaction based assays that target specific pneumococcal virulence factors for the typical streptococc streptococcus . pneumoniae, such as autolysin a which is the major pneumococcal autolysin and the capsular polysaccharide biosynthesis gene a which is a conservedpneumococcal capsular polysaccharide gene , also alib-like orf2 (a gene that usually found in the capsular region of non-capsulated pneumococci; these genetic markers have been used to differentiate s. pneumoniae from other related species.

Eligibility criteria:
inclusion criteria: * all patients showing signs of respiratory tract infection exclusion criteria: * no exclusion criteria
a study to assess the efficacy and safety of abatacept in adults with active primary sjögrens syndrome

Conditions: Sjogrens Disease

Summary: the purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with sjögren's syndrome.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * eular sjögren's syndrome disease activity index (essdai) score of at least 5 * positive anti-ss-a/ro antibody at screening * meet the 2016 american college of rheumatology (acr) / european league against rheumatism classification criteria for sjögren's syndrome (eular ss) exclusion criteria: * secondary sjögrens syndrome * active life-threatening or organ-threatening complications of sjögren's-syndrome * other medical condition associated with sicca syndrome other protocol defined inclusion/exclusion criteria could apply
the effect of online transtheoretic model based health education on overweight university students

Conditions: Public Health Nursing

Summary: aim: in this study, it was aimed to determine the effect of health education given to overweight university students based on the transtheoretic model (ttm) on nutrition and physical activity behaviors. materials and methods: the research was conducted in a randomized controlled experimental design. the sample of the study consisted of 54 students, 27 of which were in the experimental group and 27 in the control group, who met the inclusion criteria between october 2021 and november 2021. students were divided into nutrition and exercise change stages groups according to ttm. the students in the experimental group were given one-on-one health education in accordance with the ttm change stages, using the online method. in the study, data were collected using the sociodemographic form, nutrition and exercise stage determination form according to ttm, nutrition change processes scale (ncps) and exercise change processes scale (ecps). chi-square test and t test for dependent and independent groups were used in the analysis of the data obtained. statistical significance level was accepted as p\<0.05.


Eligibility criteria:
inclusion criteria: * agreeing to participate in the research, * university students without chronic diseases * bmi level between 24.9 and 30, * open to communication and cooperation, * internet and smartphone/tablet/computer etc. owner. exclusion criteria: * bmi level of 24.9 and below, * using any drug, * who left the research voluntarily. * under the age of 18

Keywords: transtheoretical model public health nursing university student
the relationship between xinkang-i and chronic heart failure

Conditions: Traditional Chinese Medicine

Summary: background: heart failure is the severe and terminal stage of various heart diseases, which is characterized by high morbidity, mortality and readmission. there are few studies on the relationship between xinkang-i(xk-i) and chronic heart failure. objective: to explore the relationship between xk-i and chronic heart failure. methods/design: the trial is a single-center, single-blind, randomized study (1:1). it will recruit 110 patients with chronic heart failure who syndrome of qi deficiency yang deficiency and blood stasis. the intervention group will receive not only western medicine, but also xk-i. the primary end points will be the changes in oxygen consumption volume of anaerobic threshold (vo2at), maximum oxygen volume uptake (vo2max), and 6-minute walking distance after 8 weeks of treatment. both groups will receive 8 weeks of treatment. ethics and dissemination: ethical approval was granted by ethics committee of dongguan tcm hospital. results will be disseminated via peer-reviewed publications and presentations at international conferences.


Eligibility criteria:
inclusion criteria: 1. history of chf or clinical findings of chf for more than 3 months. chf was diagnosed in accordance with the european society of cardiology's 2021 guidelines for the diagnosis and treatment of acute and chronic heart failure. 2. patients ranged in age from 18 to 85. 3. cardiac function was graded at grade ii-iv (new york heart association functional class). 4. patients who had not used traditional chinese medicine for treating heart failure within 1 week before enrollment; 5. written informed consent will be obtained. exclusion criteria: 1. acute cardiac insufficiency, acute myocarditis, severe valvular heart disease, malignant arrhythmia, obstructive cardiomyopathy, pericardial tamponade, constrictive pericarditis or acute coronary syndrome 2. severe lung, liver or kidney dysfunction 3. nervous and hematopoietic system 4. malignant tumors 5. hemodynamic nstability 6. pulmonary embolism 7. severe infection 8. pregnant or lactating 9. refusal to provide written informed consent for this study